Our partner is developing a treatment for two formidable diseases that are the leading cause of death and liver transplants worldwide. They are working towards a treatment that will improve lipid metabolism and anti-inflammatory properties to target diseases such as Atherosclerosis and NAFLD/NASH.

This critical interim executive leader was responsible for managing all aspects of our partner’s activities, including setting up and implementing the company’s overall strategy, goals and timelines, business development, finance, and other company related matters.